Transient inhibition of NF-κB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation

Cancer Science

Volumn 100, Issue 4, 2009, Pages 737-746

  Dabaghmanesh, Nazanin ^a   Matsubara, Aiko ^a,b   Miyake, Ariko ^a   Nakano, Kazumi ^a   Ishida, Takaomi ^a   Katano, Harutaka ^c   Horie, Ryoichi ^d   Umezawa, Kazuo ^e   Watanabe, Toshiki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d KITASATO UNIVERSITY   (Japan)

^e KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOPTOSIS INHIBITOR; CASPASE 3; CASPASE 8; CASPASE 9; CHEMOKINE RECEPTOR CCR5; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MYC PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PROTEIN BAG3; PROTEIN BCL XL; PROTEIN DEDD2; PROTEIN MIF; PROTEIN PPP1R15A; PROTEIN SSPI; SOMATOMEDIN RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CYCLOHEXANONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN HERPESVIRUS 8; MALE; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; UPREGULATION; VIRUS REACTIVATION; VIRUS REPLICATION; CELL STRAIN K 562; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; HELA CELL; HUMAN; LEUKEMIA CELL LINE; METABOLISM; NICK END LABELING; TIME; TUMOR CELL LINE; VIROLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CASPASE 3; CASPASE 8; CASPASE 9; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOHEXANONES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HELA CELLS; HERPESVIRUS 8, HUMAN; HUMANS; IN SITU NICK-END LABELING; JURKAT CELLS; K562 CELLS; LYMPHOMA, PRIMARY EFFUSION; NF-KAPPA B; TIME FACTORS;

EID: 67449103166     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01083.x     Document Type: Article

References (45)

1. Nador R, Cesarman E, Chadburn A et al. Primary effusion lymphoma: A distinct clinopathologic entity associated with the Kaposi's sarcoma associated herpes virus. Blood 1996; 88: 645-56.
2. Klepfish A, Sarid R, Shtalrid M et al. Primary effusion lymphoma (PEL) in HIV-negative patients - a distinct clinical entity. Leuk Lymphoma 2001; 41: 439-43.
3. Boulanger E, Gérard L, Gabarre J et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with aids. J Clin Oncol 2005; 23: 4372-80.
4. Hengge UR, Ruzicka T, Tyring SK et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: Pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002; 2: 344-52.
5. Jarviluoma A, Ojala PM. Cell signaling pathways engaged by KSHV. Biochim Biophys Acta 2006; 1766: 140-58.
6. Sun Q, Matta H, Chaudhary PM. The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation. Blood 2003; 101: 1956-61.
7. Chaudhary PM, Jasmin A, Eby MT et al. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 1999; 18: 5738-46.
8. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004; 199: 993-1003.
9. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96: 2537-42.
10. Keller SA, Hernandez-Hopkins D, Vider J et al. NF-κB is essential for progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006; 107: 3295-302.
11. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004; 5: 392-401.
12. Chen LF, Greene WC. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med 2003; 81: 549-57.
13. Matsumoto N, Ariga A, To-e S et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000; 10: 865-9.
14. Umezawa K, Chaicharoenpong C. Molecular design and biological activities of NF-kappaB inhibitors. Mol Cells 2002; 14: 163-7.
15. Watanabe M, Ohsugi T, Shoda M et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005; 106: 2462-71.
16. Watanabe M, Dewan Md. Z, Taira M et al. IκBα independent induction of NF-κB and its inhibition by DHMEQ in Hodgkin-Reed-Sternberg cells. Lab Invest 2007; 87: 372-82.
17. Horie R, Watanabe M, Okamura T et al. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 2006; 20: 800-6.
18. Watanabe M, Dewan Md Z, Okamura T et al. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005; 114: 32-8.
19. Nishimura D, Ishikawa H, Matsumoto K et al. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int J Oncol 2006; 29: 713-9.
20. Matsumoto G, Muta M, Umezawa K et al. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor. Int J Oncol 2005; 27: 1247-55.
21. Matsumoto G, Namekawa J, Muta M et al. Targeting of nuclear factor kappaB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin Cancer Res 2005; 11: 1287-93.
22. Drexler HG, Uphoff CC, Gaidano G, Carbone A. Lymphoma cell lines: In vitro models for the study of HHV-8* primary effusion lymphomas (body cavity-based lymphomas). Leukemia 1998; 12: 1507-17.
23. Katano H, Hoshino Y, Morishita Y et al. Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. J Med Virol 1999; 58: 394-401.
24. Lenardo MJ, Baltimore D. NF-kappaB: A pleiotropic mediator inducible and tissue-specific gene control. Cell 1989; 58: 227-9.
25. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucl Acids Res 1991; 19: 2499.
26. Miyake A, Dewan MdZ, Ishida T et al. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-κB inhibitor DHMEQ. Microbes Infect 2008; 10: 748-56.
27. Krishnan HH, Naranatt PP, Smith MS et al. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J Virol 2004; 78: 3601-20.
28. Yoo SM, Zhou FC, YeFC et al. Early and sustained expression of latent and host modulating genes in coordinated transcriptional program of KSHV productive primary infection of human primary endothelial cells. Virology 2005; 343: 47-64.
29. O'Donovan M, Silva I, Uhlmann V et al. Expression profile of human herpesvirus 8 (HHV-8) in pyothorax associated lymphoma and in effusion lymphoma. Mol Pathol 2001; 54: 80-5.
30. Ghosh SK, Wood C, Boise LH et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappaB. Blood 2003; 101: 2321-7.
31. Brown HJ, Song MJ, Deng H et al. NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol 2003; 77: 8532-40.
32. Ohsugi T, Horie R, Kumasaka T et al. In vivo antitumor activity of the NF-kB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 2005; 26: 1382-8.
33. Ohsugi T, Kumasaka T, Ishida A et al. In vitro and in vivo antitumor activity of the NF-κB inhibitor DHMEQ in the human T-cell leukemia virus type 1-transformed cell line, HUT-102. Leuk Res 2006; 30: 90-7.
34. Liu L, Eby MT, Rathore N et al. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the IkappaB kinase complex. J Biol Chem 2002; 277: 13745-51.
35. Field N, Low W, Daniels M et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 2003; 116: 3721-8.
36. Pierce JW, Schoeenleber R, Jesmok G et al. Novel inhibitors of cytokine-induced IkappaB-alpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997; 272: 21096-103.
37. Berger N, Bassat HB, Klein BY, Laskov R. Cytotoxicity of NF-κB inhibitors Bay 11-7085 and caffeic acid phenethyl ester to Ramos and other human B-lymphoma cell lines. Exp Hemaol 2007; 35: 1495-509.
38. Weinstein IB. Disorders in cell circuitry during multi-stage carcinogenesis. Caricinogenesis 2000; 21: 857-64.
39. Sharma SV, Fischbach MA, Haber DA, Settleman J. 'Oncogene shock' explaining oncogene addiction through differential signal activation. Clin Cancer Res 2006; 12 (14 Suppl.): 4392s-95s.
40. Sharma SV, Settleman J. Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21: 3214-31.
41. Nieminen AI, Partanen JI, Klefstrom J. c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. Cell Cycle 2007; 6: 2464-72.
42. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-56.
43. Cowling V, Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: Absolute requirement for removal of caspase-6 prodomain. Cell Death Differ 2002; 9: 1046-56.
44. Sgarbanti M, Arguello M, Tenover BR et al. A requirement for NF-kappaB induction in the production of replication-component HHV-8 virions. Oncogene 2004; 23: 5770-80.
45. Cahir-McFarland ED, Carter K, Rosenwald A et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 2004; 78: 4108-19.